The effect of topical bromfenac on intraretinal and subretinal fluid in neovascular age-related macular degeneration

被引：1
作者：
Abdolrahimzadeh, Solmaz [1 ]
Fameli, Valeria [2 ]
Di Tizio, Federico [1 ]
Di Staso, Federico [1 ]
Fenicia, Vito [1 ]
Scuderi, Gianluca [1 ]
机构：
[1] Sapienza Univ Rome, St Andrea Hosp, Neurosci Mental Hlth & Sensory Organs Dept, Ophthalmol Unit, Via Grottarossa 1035-1039, I-00189 Rome, Italy
[2] Sapienza Univ Rome, Dept Sense Organs, Ophthalmol Unit, Rome, Italy
来源：
JOURNAL OF CURRENT OPHTHALMOLOGY | 2020年 / 32卷 / 02期
关键词：
Age-related macular degeneration; Bromfenac; Intraretinal fluid; Spectral domain optical coherence tomography; Subretinal fluid; RANDOMIZED CONTROLLED-TRIAL; KETOROLAC EYEDROPS; RANIBIZUMAB; COMBINATION; NEPAFENAC; THERAPY; 0.09-PERCENT;
D O I：
10.4103/JOCO.JOCO_105_20
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Purpose: To report the effect of topical bromfenac, a non-steroidal anti-inflammatory drug (NSAID), in a case of neovascular age-related macular degeneration (AMD). Methods: An 85-year-old woman presented with a complaint of visual acuity reduction in the right eye. Comprehensive ophthalmological examination and retinal imaging were performed. Results: Best corrected visual acuity was 2/100. Fundus examination showed reticular pseudodrusen and a small hemorrhage in the fovea. Fluorescein angiography showed an active neovascular membrane. Spectral-domain optical coherence tomography (SD-OCT) confirmed diagnosis and revealed subretinal and intraretinal fluid. The patient refused recommended intravitreal anti-vascular endothelial growth factor treatment and received topical bromfenac 0.09% twice daily. Follow-up with SD-OCT showed subretinal followed by intraretinal fluid reduction at 16 weeks after treatment. Conclusion: Short-term reduction of subretinal and intraretinal fluid was observed with topical bromfenac monotherapy in neovascular AMD.
引用
收藏
页码：203 / 206
页数：4
相关论文
共 20 条
  • [1] Abdolrahimzadeh S, 2015, BIOMED RES INT, V2015
  • [2] Optical coherence tomography evidence of macular ganglion cell-inner plexiform layer thinning in eyes with subretinal drusenoid deposits
    Abdolrahimzadeh, Solmaz
    Parisi, Francesco
    Marcelli, Michela
    Giustolis, Rosalia
    Gharbiya, Magda
    [J]. EYE, 2019, 33 (08) : 1290 - 1296
  • [3] Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration
    Amissah-Arthur, K. N.
    Panneerselvam, S.
    Narendran, N.
    Yang, Y. C.
    [J]. EYE, 2012, 26 (03) : 394 - 399
  • [4] Use of nepafenac (Nevanac (R)) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
    Chen, Eric
    Benz, Matthew S.
    Fish, Richard H.
    Brown, David M.
    Wong, Tien P.
    Kim, Rosa Y.
    Major, James C.
    [J]. CLINICAL OPHTHALMOLOGY, 2010, 4 : 1249 - 1252
  • [5] New pharmacologic approaches to therapy for age-related macular degeneration
    Eter, Nicole
    Krohne, Tim U.
    Holz, Frank G.
    [J]. BIODRUGS, 2006, 20 (03) : 167 - 179
  • [6] PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Pilot Study
    Flaxel, Christina
    Schain, Mitchell B.
    Hamon, Sara C.
    Francis, Peter J.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (03): : 417 - 423
  • [7] TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    Gomi, Fumi
    Sawa, Miki
    Tsujikawa, Motokazu
    Nishida, Kohji
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (09): : 1804 - 1810
  • [8] Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
    Guymer, Robyn H.
    Markey, Caroline M.
    McAllister, Ian L.
    Gillies, Mark C.
    Hunyor, Alex P.
    Arnold, Jennifer J.
    [J]. OPHTHALMOLOGY, 2019, 126 (05) : 723 - 734
  • [9] VITREOUS NONSTEROIDAL ANTIINFLAMMATORY DRUG CONCENTRATIONS AND PROSTAGLANDIN E2 LEVELS IN VITRECTOMY PATIENTS TREATED WITH KETOROLAC 0.4%, BROMFENAC 0.09%, AND NEPAFENAC 0.1%
    Heier, Jeffrey S.
    Awh, Carl C.
    Busbee, Brandon G.
    Waterbury, L. David
    Daniel, Paul
    Stoller, Glenn L.
    Cleary, Tina S.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (09): : 1310 - 1313
  • [10] The epidemiology of age-related macular degeneration
    Klein, R
    Peto, T
    Bird, A
    Vannewkirk, MR
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (03) : 486 - 495
12